sorafenib

sorafenib

美 　英

• 網絡索拉非尼；索拉菲尼；多吉美

例句

Hepatology Digest: The last thing I would like to ask you about is sorafenib .

國際肝病：最后我想問的是索拉非尼。

We are currently doing a multi-centre trial looking to see if the addition of sorafenib in adjuvant therapy will be beneficial.

目前，我們正在進行一項多中心臨床試驗，研究在輔助治療方案中添加索拉非尼是否有效。

For those patients with advanced HCC, who have had surgical resection, with the surgery impact the safety and efficacy of sorafenib ?

對于已進行了手術的晚期肝癌患者，手術會影響索拉非尼的安全性和療效嗎？

In the latter scenario, sorafenib should also constitute the control arm of these trials.

在近來的方案中，索拉菲尼將成為這些實驗中的控制臂。

Sorafenib is currently approved in the United States and other countries for treatment of advanced renal cell carcinoma.

當前索拉非尼在美國和其他國家被批準用來治療晚期腎細胞癌。

The combination of sorafenib and doxorubicin in patients with advanced HCC has not been evaluated in a phase 2 or 3 trial.

目前還沒有2期或3期試驗對索拉非尼與多柔比星聯用治療晚期HCC患者進行評價。

Investigators and cooperative groups are currently evaluating sorafenib in various breast cancer treatment settings, according to Bayer.

據拜耳消息，研究人員和投資方目前正在對索拉非尼應用于各種乳腺癌治療情況進行評測。

Consequently, sorafenib will become the standard of care in advanced cases, and the control arm for future trials.

同時，索拉菲尼將會是早期病例的標準治療方法和未來試驗的對照藥。

The study was stopped prematurely when a planned interim analysis showed sorafenib's significant superiority over placebo.

根據計劃，當中期分析顯示索拉非尼的效果明顯優于安慰劑時，研究會過早的中止。

Treatment duration was a median of 23 weeks in the sorafenib group and 19 weeks in the placebo group.

治療時間中位數在索拉非尼組為23周，在安慰劑組為19周。

OBJECTIVE To synthesize sorafenib a new anti-tumor drug.

目的合成抗腫瘤新藥索拉非尼。

Hepatology Digest: There is obviously a lot of talk about sorafenib at this year's meeting.

國際肝病：在今年的會議上有很多關于索拉菲尼的研究報道。

Median overall survival was 46 weeks in the sorafenib group and 34 weeks in the placebo group (HR 0. 69, P =. 00058).

在索拉非尼組的中位數總生存率為46周，而在安慰劑組為34周（HR0.69；P=.00058）。

Hepatology Digest: Do you think that with more and more clinical trials regarding sorafenib, do you think it will update the guidelines?

《國際肝病》：隨著索拉菲尼臨床試驗數據的不斷豐富，您認為索拉菲尼將會改變當前肝癌的診療指南嗎？